key: cord-0985459-p8xpavbg
authors: Ayoubkhani, D.; Khunti, K.; Nafilyan, V.; Maddox, T.; Humberstone, B.; Diamond, I.; Banerjee, A.
title: Epidemiology of post-COVID syndrome following hospitalisation with coronavirus: a retrospective cohort study
date: 2021-01-15
journal: nan
DOI: 10.1101/2021.01.15.21249885
sha: ea22134bb180a572552864731178c7d76dd6dab2
doc_id: 985459
cord_uid: p8xpavbg

Objectives: The epidemiology of post-COVID syndrome (PCS) is currently undefined. We quantified rates of organ-specific impairment following recovery from COVID-19 hospitalisation compared with those in a matched control group, and how the rate ratio (RR) varies by age, sex, and ethnicity. Design: Observational, retrospective, matched cohort study. Setting: NHS hospitals in England. Participants: 47,780 individuals (mean age 65 years, 55% male) in hospital with COVID-19 and discharged alive by 31 August 2020, matched to controls on demographic and clinical characteristics. Outcome measures: Rates of hospital readmission, all-cause mortality, and diagnoses of respiratory, cardiovascular, metabolic, kidney and liver diseases until 30 September 2020. Results: Mean follow-up time was 140 days for COVID-19 cases and 153 days for controls. 766 (95% confidence interval: 753 to 779) readmissions and 320 (312 to 328) deaths per 1,000 person-years were observed in COVID-19 cases, 3.5 (3.4 to 3.6) and 7.7 (7.2 to 8.3) times greater, respectively, than in controls. Rates of respiratory, diabetes and cardiovascular events were also significantly elevated in COVID-19 cases, at 770 (758 to 783), 127 (122 to 132) and 126 (121 to 131) events per 1,000 person-years, respectively. RRs were greater for individuals aged <70 than [≥]70 years, and in ethnic minority groups than the White population, with the biggest differences observed for respiratory disease: 10.5 [9.7 to 11.4] for <70 years versus 4.6 [4.3 to 4.8] for [≥]70 years, and 11.4 (9.8 to 13.3) for Non-White versus 5.2 (5.0 to 5.5) for White. Conclusions: Individuals discharged from hospital following COVID-19 face elevated rates of multi-organ dysfunction compared with background levels, and the increase in risk is neither confined to the elderly nor uniform across ethnicities. The diagnosis, treatment and prevention of PCS require integrated rather than organ- or disease-specific approaches. Urgent research is required to establish risk factors for PCS.

In the early coronavirus disease pandemic in the UK, approximately 6% of people were thought to have had severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection, rising to 13% in London. [1] The majority of the research, health service and media response to the virus has focused on direct (through infection) and indirect (through impact on individual behaviours and health system changes) effects of COVID-19 on mortality [2] and short-term impacts. [3, 4] However, the longer-term effects on morbidity need to be studied in order to plan for effective healthcare delivery and capacity.

Since SARS-CoV2 infection was recognised in late 2019, academic and clinical emphasis has been on respiratory manifestations. [5] However, there is increasing evidence for direct multi-organ effects, [6] [7] [8] [9] [10] as well as indirect effects on other organ systems and disease processes, such as cardiovascular diseases and cancers, through changes in healthcare delivery and patient behaviours. [11] [12] [13] Although the long-term impact of COVID-19 on individuals and health systems is becoming clear, there is an urgent need for investigation across organ systems.

Long COVID, or post-COVID syndrome (PCS), is not a single condition, and has been defined by the National Institute for Health and Care Excellence (NICE) as "signs and symptoms that develop during or following an infection consistent with COVID-19 which continue for more than 12 weeks and are not explained by an alternative diagnosis." [14] Guidelines recommend referral to PCS assessment clinics if post-COVID symptoms persist for 6-12 weeks. [14] Pre-existing conditions and risk factors are predictors of acute COVID-19 outcomes (such as intensive care admissions and mortality [2] ), but the epidemiology of PCS has been less well defined [15, 16] due to unclear medium-and long-term pathophysiology across organ systems. As PCS clinics are implemented, characterisation of disease epidemiology will aid appropriate diagnosis, care, public health interventions and policy, and resource planning.

The existing evidence base shows large variations in estimates of PCS prevalence and incidence due to differences in study populations, recruitment methods, follow-up periods, and sample sizes. Most studies to date have concentrated on symptoms associated with PCS rather than organ impairment, and few have made use of a control group permitting the inference of counterfactual outcomes. Therefore, using national electronic health records and death registrations for individuals in England, we quantified the incidence of mortality, health service utilisation, and organ-specific impairment following discharge from hospital with COVID-19. We estimated rate ratios of post-discharge adverse events compared with those in a matched control group, and heterogeneity in this rate ratio across demographic groups. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

Individuals with COVID-19 were included in the study if they had a hospital episode starting from 1 January 2020 and ending by 31 August 2020 with a primary diagnosis of COVID-19, identified using International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) codes U07.1 (virus identified) and U07.2 (virus not identified); that is, by a positive laboratory test or clinical diagnosis. Individuals with COVID-19 were excluded if they had not been discharged alive by 31 August 2020 or had an unknown date of birth and/or sex. The index date was set to date of discharge following the first hospital episode with COVID-19 as the primary diagnosis.

Candidate controls comprised individuals who: (i) did not meet the COVID-19 inclusion criteria specified above; (ii) had at least one GDPPR record between 1 January 2019 (one year before the start of the follow-up period) and 30 September 2020 (the end-of-study date); and (iii) had not died before 1 January 2020. Each control had the same index date as their matched COVID-19 case.

All individuals were followed-up from index date to 30 September 2020 or date of death (whichever was earlier) for the following adverse events: all-cause mortality; hospital readmission for any reason; respiratory disease; major adverse cardiovascular event (MACE, a composite of heart failure [HF], myocardial infarction [MI], stroke, and arrhythmia); diabetes (type 1 or 2); chronic kidney disease (CKD) stages 3-5 (including dialysis and kidney transplant); and chronic liver disease (CLD).

Respiratory, MACE, diabetes, CKD and CLD events were identified from diagnoses made in primary care and in hospital (using only primary ICD-10 codes for the latter), except for the arrythmia component of MACE for which primary care data were not available.

COVID-19 cases were matched to controls on baseline demographic and clinical characteristics that may confound the relationship between COVID-19 and outcomes (Supplementary Table 1) , established over the ten-year look-back period 1 January 2010 to 31 December 2019. Comorbidities were identified from diagnoses made in primary care and in hospital (using both primary and secondary ICD-10 codes for the latter).

Distributions of baseline characteristics were compared between individuals with COVID-19 and a random 0.5% sample of the general population using Chi squared tests and standardised differences in proportions, where a standardised difference in excess of 10% was taken as evidence of large imbalance between the groups. [17] COVID-19 cases and controls were matched using exact 1:1 matching. Matched pairs were discarded if the control died before the corresponding COVID-19 case's index date. All covariates were discretised prior to matching, including an 'Unknown' category comprising individuals with missing values.

We computed rates of adverse events per 1,000 person-years of exposure time in COVID-19 cases and controls, and derived rate ratios contrasting these event rates, to estimate the 'average treatment effect on the treated.' 95% confidence intervals (CIs) were estimated using the Poisson distribution.

We estimated events rates for the full study population firstly by using all adverse events, and secondly by considering only new-onset cases (that is, where the individual did not have a diagnosis for the condition over the ten-year look-back period). All-diagnoses event rates were stratified by sex, coarse age group (<70 years, ≥70 years), and coarse ethnic group (White, Non-White). In secondary analysis, individuals with COVID-19 were stratified according to whether they were admitted to an intensive care unit (ICU) during their hospital spell as a measure of disease severity. All statistical analyses were conducted using R version 4.0.2.

Of 86,955 individuals in hospital with COVID-19 during the study period, 53,795 (61.9%) had been discharged alive by end-of-study ( Figure 1 ). After excluding individuals with unknown age or sex and those who could not be matched to a control, 47,780 COVID-19 cases (4,745 ICU and 43,035 non-ICU) were included in the analysis, representing 90.8% of those discharged alive with known age and sex. Mean follow-up times were 140 days (standard deviation [SD] 50 days, maximum 253 days) for COVID-19 cases and 153 days (SD 33 days, maximum 253 days) for controls. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint were male. Compared with the general population, individuals in hospital with COVD-19 were more likely to be aged ≥50 years, male, living in a deprived area, a former smoker, and overweight or obese (Table 1) . Individuals with COVID-19 were also more likely to be comorbid than the general population, with a higher prevalence of prior hospitalisation and all measured pre-existing conditions (most notably hypertension, MACE, respiratory disease and diabetes).

Of 47,780 individuals in hospital with COVID-19 over the study period, 29.4% were re-admitted and 12.3% died following discharge ( Table 2 ). These events occurred at rates of 766 (CI: 753 to 779) readmissions and 320 (312 to 328) deaths per 1,000 person-years, which were 3.5 (3.4 to 3.6) and 7.7 (7.2 to 8.3) times greater, respectively, than those in matched controls. Respiratory disease was diagnosed in 14,140 individuals (29.6%) following discharge, with 6,085 of these being new-onset cases; the resulting event rates of 770 (758 to 783) and 539 (525 to 553) per 1,000 person-years, respectively, were 6.0 (5.7 to 6.2) and 27.3 (24.0 to 31.2) times greater than those in controls.

Post-discharge diagnoses of diabetes, MACE, CKD and CLD were made for 4.9% In secondary analysis, rates of post-discharge adverse events remained significantly elevated among individuals with COVID-19 compared with matched controls after stratifying by ICU versus non-ICU admission (Supplementary Table 3 ). Individuals requiring ICU admission experienced greater rates of post-discharge respiratory disease and diabetes than those not in ICU, but the opposite was true for rates of death, readmission and MACE.

Rates of all post-discharge adverse events were greater in individuals with COVID-19 aged ≥70 years than <70 years, while rates of all events other than diabetes were greater in the White ethnic group than the Non-White group (Supplementary Table 4 ). However, the rate ratio of adverse events (contrasting COVID-19 cases and matched controls) was greater in individuals aged <70 years than ≥70 years for all event types ( Figure 3) , with the biggest differences in rate ratios being observed for death ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.15.21249885 doi: medRxiv preprint were most pronounced for respiratory disease, at 11.4 (9.8 to 13.3) for individuals in the Non-White group compared with 5.2 (5.0 to 5.5) in the White group. Differences in rate ratios of adverse events between males and females were generally small. See Supplementary Table 4 for detailed results.

In the largest study to-date to examine PCS in individuals hospitalised with COVID-19, comprising 47,780 COVID-19 cases with matched controls, we describe three major findings. Firstly, COVID-19 hospitalisation was associated with increased risk of readmission and death following discharge, relative to that in individuals of similar demographic and clinical profiles over the same period; nearly a third of people post COVID-19 hospital discharge were re-admitted and more than 1 in 10 died.

Secondly, rates of post-discharge multi-organ dysfunction were elevated in individuals with COVID-19 compared with those in the matched control group, suggesting extrapulmonary pathophysiology.

Diabetes and MACE were particularly common, both when considering all post-discharge events (which may reflect a combination of new-onset cases and exasperation of pre-existing conditions) and only incident cases.

Finally, the absolute risk of post-discharge adverse events was greater for individuals aged ≥70 years than <70 years, and for individuals of White ethnic background than in the Non-White group.

However, when contrasted against the background rates of adverse events that might be expected to occur in these groups in the general population, younger and ethnic minority individuals faced greater relative risks than those aged ≥70 years and those in the White group, respectively.

Our results are consistent with hypothesised biological mechanisms associated with respiratory, [18] cardiovascular, [19] metabolic, [20] renal, [10] and hepatic [8] involvement in COVID-19, and extend the early evidence base surrounding PCS which has been described as being "limited" and generally of low quality. [21] In a more recent study of 1,775 US veterans hospitalised with COVID-19, 20% were readmitted and 9% died within 60 days of discharge; [22] after restricting follow-up time in our study to the same duration, we found similar prevalence rates of 23% and 9%, respectively. The US study did not analyse organ-specific endpoints and was conducted in a specific population; we can thus now add that COVID-19 is associated with post-discharge manifestations in a range of organs in the general population. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Multi-organ involvement following COVID-19 infection was detected in 201 low-risk individuals in the UK (18% hospitalised with COVID- 19) , with impairment of the lungs (33%), heart (32%), kidneys (12%) and liver (10%) found to be common. [23] These prevalence rates are higher than those estimated in our study, though the degree of organ impairment was generally found to be mild and therefore likely to be subclinical.

In a case series of 213 discharged individuals with COVID-19 in the US, 10% were re-admitted and 2% died over a median follow-up time of 80 days, [24] compared with our much greater estimates of 29% and 12%, respectively (but over a longer median follow-up time of 160 days). However, the small sample size precludes extrapolation to broader populations.

COVID-19 was associated with increased odds of acute kidney injury, renal replacement therapy, insulin use, pulmonary embolism, stroke, myocarditis, arrythmia, and elevated troponin in US veterans hospitalised with COVID-19 versus a control of seasonal influenza. [25] The index event was admission rather than discharge, so the results do not necessarily capture long-term outcomes of COVID-19, but they are indicative of physiological changes in multiple organs at the acute phase of the disease and therefore support our own findings.

Pulmonary lesions were found in hospitalised COVID-19 patients in Wuhan, China, though only at a short follow-up duration of three weeks post-discharge. [26] Cardiovascular magnetic resonance (CMR) imaging revealed myocardial inflammation in German participants who recovered from acute COVID-19, [6] while myocarditis was also detected by CMR imaging in post-acute US college athletes. [27] These studies are suggestive of pulmonary and myocardial involvement in individuals with COVID-19 and, although small sample sizes and highly specific study populations make it difficult to generalise the results, they shed some light on possible pathophysiological mechanisms that underly our own findings.

With over 3 million people in the UK having tested positive for COVID-19 at the time of writing, [28] and many more who had the disease but never received a test, our findings suggest that the longterm burden of COVID-related morbidity on hospitals and broader healthcare systems is likely to be substantial. PCS comes on a backdrop of healthcare challenges, particularly sustainable high-quality care for long-term conditions: inequalities in health, access and provision; incomplete pathways across community and hospital care; inadequate research translation to clinical practice; and insufficient resources. Our findings across organ systems suggest that the diagnosis, treatment and prevention of PCS will require integrated rather than organ-or disease-specific approaches. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.15.21249885 doi: medRxiv preprint

The main strength of our study lies in its size and completeness, as it includes all individuals in England in hospital with COVID-19 observed over a follow-up period of up to several months. Use of a matched control group allowed rates of post-discharge adverse events in individuals with COVID-19 to be compared against counterfactual outcomeswhat might have been observed given the background risk in these individuals.

Like all observational studies, we cannot rule out the possibility of residual confounding (for example, due to biomarkers or socio-economic exposures omitted from our matching set) which precludes our ability to draw definitive causal conclusions. The limited number of events in the control group meant we were unable to disaggregate rate ratios stratified by age and ethnicity beyond broad '<70 years verses ≥70 years' and 'White versus Non-White' comparisons, despite the likelihood of heterogeneity in outcomes within these groups. The threshold for hospital admission may be lower among individuals with a recent history of COVID-19 than in the general population, and rates of diagnoses in general may have decreased as an indirect result of the pandemic, particularly among people who were not admitted to hospital with COVID-19. We did not have access to testing data and thus were unable to remove individuals infected with COVID-19 who did not require hospitalisation from our control group. Moreover, our results are unlikely to fully capture the lived experience of individuals living with PCS who were possibly asymptomatic and untested at the time of infection. Multi-organ manifestations beyond the acute phase of COVID-19 infection have been identified in nonhospitalised individuals, [23] who were beyond the scope of our study, and we did not capture symptoms such as fatigue, disturbance of taste and smell, and anxiety, which have been widely reported by individuals with suspected PCS. [21] Conclusions Individuals discharged from hospital following acute COVID-19 face elevated rates of mortality, readmission and multi-organ dysfunction compared with the background levels that exist for these individuals, and the relative increase in risk is neither confined to the elderly nor uniform across ethnic groups. Urgent research is required to further understand the risk factors for PCS, so that treatment provision can be better targeted to demographically and clinically at-risk populations. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. 

In accordance with NHS Digital's Information Governance (IG) requirements, it is not possible for the study data to be shared.

NHS Digital approved access to the data for this study following a favourable recommendation from its Independent Group Advising on the Release of Data (IGARD). Ethical approval was obtained from the National Statistician's Data Ethics Advisory Committee [NSDEC (20) 12].

There was no external funding for this study. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.15.21249885 doi: medRxiv preprint Tables and figures   Table 1 . Baseline characteristics of individuals in hospital with COVID-19 in England compared with those of a random sample from the general population Table 2 . Counts and rates of death, readmission and respiratory disease contrasting individuals with COVID-19 in England discharged from hospital by 31 August 2020 with matched controls is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; Figure 3 . Rate ratios of adverse events contrasting individuals with COVID-19 in England discharged from hospital by 31 August 2020 with matched controls, stratified by demographic factors is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 15, 2021. ;

Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults

Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study

Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study

Factors associated with COVID-19-related death using OpenSAFELY

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease

Pathologic features of COVID-19: A concise review

Liver injury in COVID-19: The current evidence

The Impact of SARS-Cov-2 Virus Infection on the Endocrine System

COVID-19 and the kidney: what we think we know so far and what we don't

Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK

Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study

Estimating the effect of reduced attendance at emergency departments for suspected cardiac conditions on cardiac mortality during the COVID-19 pandemic

National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the longterm effects of COVID-19

Themed Review: Living with Covid19

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

Long term respiratory complications of covid-19

Anticipating the long-term cardiovascular effects of COVID-19

New-Onset Diabetes in Covid-19

Characterising long-term covid-19: a rapid living systematic review

Readmission and Death After Initial Hospital Discharge Among Patients With COVID-19 in a Large Multihospital System

Multi-organ impairment in low-risk individuals with long COVID

Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system

Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study

The pulmonary sequalae in discharged patients with COVID-19: a short-term observational study

Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection

COVID-19 cases were matched to controls on baseline demographic characteristics (age, sex, ethnicity, region, Index of Multiple Deprivation quintile, smoking status) and clinical histories (hypertension, major adverse cardiovascular event, respiratory disease, chronic kidney disease, chronic liver disease, diabetes, cancer). ). Rates and rate ratios for CKD could not be stratified by ethnic group due to